Community Interviews
Morie A. Gertz, MD, chair, General Internal Medicine, Mayo Clinic Comprehensive Cancer Center, discusses the rationale for the phase 3 AFFIRM-AL trial (NCT04973137…
The ANDROMEDA trial is a trial that is extremely important for patients who have systemic light chain or AL-amyloidosis. I'd like to begin by thanking Janssen…
ESPN's Jeremy Schaap was among those who received a text from Matt Millen on Dec. 23 that read, "It's on!" followed by a heart emoji.
Millen, who had been…
Dr. Jose Nativi is a cardiologist and director of the amyloidosis program at University of Utah Health Care and Huntsman Cancer Institute. He explains what…
In an interview with Rare Disease Report, Mathew Maurer, MD, Arnold and Arlene Professor of Cardiology at Columbia University, explained the standard of care and…
Much like multiple myeloma, the treatment landscape of immunoglobulin light chain (AL) amyloidosis is rapidly expanding with novel systemic therapies, says Michael…